SCHEMBL2202964

SCHEMBL2202964

Cc1nn(-c2cccc(OC(F)(F)F)c2)c(C2CC2)c1C(=O)N1CC[C@H](N2CCCC2)[C@@H](C)C1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.40
SCN10A Q9Y5Y9 2/20 0.40
NOTUM Q6P988 1/20 0.39
KMT2A Q03164 1/20 0.38
TP53 P04637 2/20 0.37
HSD11B1 P28845 1/20 0.36
MAPT P10636 1/20 0.36
MGLL Q99685 1/20 0.36
MAPK7 Q13164 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
PIM1 P11309 1/20 0.35
SLC5A1 P13866 2/20 0.35
CHRM2 P08172 1/20 0.35
NPY5R Q15761 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2203239 0.90 SCN9A (0.40) SCN9ASCN10ANOTUMKMT2ATP53
SCHEMBL2203235 0.90 SCN9A (0.40) SCN9ASCN10ANOTUMKMT2ATP53
SCHEMBL2203241 0.90 SCN9A (0.40) SCN9ASCN10ANOTUMKMT2ATP53
SCHEMBL2197622 0.89 KMT2A (0.42) KMT2A
SCHEMBL2202253 0.87 L3MBTL3 (0.43) SCN9ASCN10ANOTUMKMT2AHSD11B1
SCHEMBL2202605 0.85 KMT2A (0.42) SCN9ASCN10ANOTUMKMT2AHSD11B1
SCHEMBL2202431 0.83 SCN9A (0.40) SCN9ASCN10ANOTUMKMT2AHSD11B1
SCHEMBL2202438 0.83 SCN9A (0.40) SCN9ASCN10ANOTUMKMT2AHSD11B1
SCHEMBL2200532 0.83 SCN9A (0.40) SCN9ASCN10ANOTUMKMT2AHSD11B1
SCHEMBL2200538 0.83 SCN9A (0.40) SCN9ASCN10ANOTUMKMT2AHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 SCN9A 3692/4885SCN10A 3975/4885NOTUM 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.